Insights on the Pulmonary Arterial Hypertension (PAH) Drugs Global Market to 2027: Increasing Prevalence of Cardiovascular and Pulmonary Disorders Drives Growth
February 03, 2023 04:58 ET
|
Research and Markets
Dublin, Feb. 03, 2023 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension (PAH) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been...
Insights on the Pulmonary Arterial Hypertension Global Market to 2027 - Advanced Oral Drugs for Pulmonary Arterial Hypertension Presents Opportunities
January 26, 2022 06:13 ET
|
Research and Markets
Dublin, Jan. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Pulmonary Arterial Hypertension (2021-2027) by Drug Class, Route of Administration, Distribution Mode, and Geography, IGR Competitive Analysis,...
Worldwide Pulmonary Arterial Hypertension Industry to 2026 - Advance Oral Drugs for Pulmonary Arterial Hypertension Present Opportunities
July 05, 2021 04:28 ET
|
Research and Markets
Dublin, July 05, 2021 (GLOBE NEWSWIRE) -- The "Global Pulmonary Arterial Hypertension Market (2021-2026) by Drug Class, Route of Administration, Distribution Mode, Geography, Competitive Analysis...
Global Pulmonary Arterial Hypertension Market Report 2021: Market Leaders Opsumit and Uptravi are Being Investigated in Clinical Trials to Potentially Support Label Expansions to CTEPH
June 09, 2021 08:58 ET
|
Research and Markets
Dublin, June 09, 2021 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension Market and Forecast Analysis to 2025" drug pipelines has been added to ResearchAndMarkets.com's offering. The report...
Worldwide Pulmonary Arterial Hypertension Industry to 2025 - Featuring Gilead Sciences, United Therapeutics and Novartis International Among Others
January 20, 2021 06:33 ET
|
Research and Markets
Dublin, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The "Global Pulmonary Arterial Hypertension (2020-2025) by Drug Class, Route of Administration, Distribution Mode, Geography, Competitive Analysis and the...
Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2020: Increasing Awareness Regarding Available Treatment Alternatives to Drive Market Growth
December 01, 2020 05:18 ET
|
Research and Markets
Dublin, Dec. 01, 2020 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension (PAH) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been...
Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency
January 06, 2016 08:00 ET
|
SteadyMed Therapeutics
VANCOUVER, British Columbia and SAN RAMON, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME), (TSX:COM) and SteadyMed Ltd. (Nasdaq:STDY), today announced that the...
SteadyMed Receives Orphan Drug Designation for Trevyent for the Treatment of Pulmonary Arterial Hypertension
January 05, 2016 07:30 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value...
SteadyMed and Cardiome Enter Into a License Agreement for the Commercialization Rights to Trevyent(R) Outside the U.S.
June 29, 2015 07:00 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif. and VANCOUVER, Canada, June 29, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug products to treat orphan...
SteadyMed Ltd. Launches Initial Public Offering
March 09, 2015 16:01 ET
|
SteadyMed Therapeutics
SAN RAMON, Calif., March 9, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd., a specialty pharmaceutical company, today announced the launch of its initial public offering of 4,250,000 ordinary shares at an...